Key Developments: Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

4,424JPY
21 Oct 2014
Price Change (% chg)

¥-47 (-1.05%)
Prev Close
¥4,470
Open
¥4,475
Day's High
¥4,510
Day's Low
¥4,410
Volume
2,106,400
Avg. Vol
2,152,429
52-wk High
¥5,170
52-wk Low
¥4,338

Search Stocks

Latest Key Developments (Source: Significant Developments)

Sucampo Pharmaceuticals Inc announces extension of AMITIZA license and collaboration agreement with Takeda
Tuesday, 14 Oct 2014 06:45am EDT 

Sucampo Pharmaceuticals Inc:Says on Oct. 9signs an amendment to existing collaboration and license agreement covering U.S and Canada for AMITIZA with Takeda Pharmaceutical Co Ltd.Amendment includes various modifications to collaboration agreement including extension of current term, minimum commercial investment during current term and various governance changes allowing Takeda additional flexibility in commercializing AMITIZA.During extended term, which will begin on Jan. 1, 2021, Takeda will split with Sucampo gross profits of branded AMITIZA for any dosage strength and form for the existing indications in the U.S. and Canada.In addition, on April 1, 2015 Takeda will no longer reimburse Sucampo for product details made by Sucampo sales representatives to healthcare professionals as well as other ancillary costs of sales force.  Full Article

R-Tech Ueno, Sucampo Pharmaceuticals, Takeda Pharmaceutical settles litigation with Anchen Pharmaceuticals and Par
Thursday, 9 Oct 2014 07:45pm EDT 

R-Tech Ueno Ltd:Sucampo, R-Tech Ueno (RTU), Takeda Pharmaceutical (Takeda) and certain affiliates of Takeda have entered into a settlement and license agreement with Anchen Pharmaceuticals, Par Pharmaceutical, Inc., and Par Pharmaceutical Companies, Inc, (collectively, Par).Agreement resolves patent litigation in U.S. related to Sucampo's AMITIZA 8 mcg and 24 mcg soft gelatin capsules.Sucampo, RTU, Takeda and Par have agreed to dismiss with prejudice the patent litigation filed in the U.S. District Court for the District of Delaware.  Full Article

Seattle Genetics and Takeda announce positive data from phase 3 AETHERA clinical trial of ADCETRIS for consolidation in post-transplant Hodgkin Lymphoma
Monday, 29 Sep 2014 06:45am EDT 

Seattle Genetics Inc and Takeda Pharmaceutical Co Ltd:Says that patients with Hodgkin lymphoma (HL) who received ADCETRIS (brentuximab vedotin) as consolidation therapy immediately following an autologous stem cell transplantation (ASCT) lived significantly longer without disease progression compared to patients who received placebo.Phase 3 clinical trial, known as AETHERA, compared the use of single agent ADCETRIS to placebo in 329 patients with HL who were at risk of relapse.ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical HL.ADCETRIS has been approved in more than 45 countries for the treatment of relapsed HL and systemic anaplastic large cell lymphoma (sALCL).ADCETRIS is not approved in the AETHERA treatment setting.  Full Article

BioMotiv and Takeda Pharmaceutical enter into strategic partnership
Thursday, 25 Sep 2014 01:15pm EDT 

Takeda Pharmaceutical Co Ltd:Says Takeda has made a strategic investment in BioMotiv and that they have formed a partnership that will leverage the strengths of both organizations to identify and develop pioneering medical innovations.Says Initial investment is $25 mln over five years.Says investment includes exclusive rights relating to programs sourced by BioMotiv specifically in the therapeutic areas of Immunology & Inflammation and Cardio-metabolic Diseases.  Full Article

Takeda and Orexigen announce FDA approval of Contrave (naltrexone HCI and bupropion HCI) extended-release tablets for chronic weight management
Thursday, 11 Sep 2014 07:00am EDT 

Orexigen Therapeutics Inc and Takeda Pharmaceuticals U.S.A., Inc:U.S. FDA approves Contrave(naltrexone HCI and bupropion HCI) extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults.Takeda is committed to providing patients with obesity with treatment options that help address their needs, and the company is planning to commercially launch Contrave in the fall of 2014.Effect of Contrave on cardiovascular morbidity and mortality has not been established.  Full Article

Takeda Pharmaceutical Co Ltd announces jury verdict
Wednesday, 3 Sep 2014 08:30pm EDT 

Takeda Pharmaceutical Co Ltd:Takeda Pharmaceutical and its wholly owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. announced that judgment was entered on the jury verdict that was returned on April 7, in the case of Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc., et al.The court has yet to rule on Takeda and Eli Lilly & Co.’s post-trial motion for a new trial, or alternatively, a significantly reduced punitive damage award.Takeda has prevailed in all five ACTOS (pioglitazone HCl) cases tried in state courts and The Allen case is the only case to reach trial in the multidistrict litigation pending in the federal courts.  Full Article

Takeda Pharmaceutical Co Ltd transfers Nippon Rinsho to Medical Tribune, Inc.
Wednesday, 3 Sep 2014 02:30am EDT 

Takeda Pharmaceutical Co Ltd:Sold all shares of Nippon Rinsho to Medical Tribune, Inc.No further details disclosed.  Full Article

R&I affirms Takeda Pharmaceutical Co Ltd's rating at "AA+" and announces negative outlook
Friday, 29 Aug 2014 02:11am EDT 

Takeda Pharmaceutical Co Ltd:Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA+".Rating outlook negative, changed from stable.  Full Article

Takeda Pharmaceutical Co Ltd reaffirms FY 2015 outlook - Conference Call
Friday, 1 Aug 2014 05:00pm EDT 

Takeda Pharmaceutical Co Ltd:Says it is maintaining FY 2015 sales and earning guidance.Says it is confident of reaching guidance of 2- 4 pct probably for sales and flat to slightly declining in core earning for FY 2015.Reported revenue of 1,691 bln yen, EPS of 135.10 yen, net income of 100.10 bln yen in FY 2014.FY 2015 revenue of 1,725 bln yen, EPS of 125.20 yen, net income of 106.66 bln yen - Thomson Reuters I/B/E/S.  Full Article

Takeda Pharmaceutical Co Ltd announces conclusion of cooperative commercialization regarding product SELTOUCH
Tuesday, 22 Jul 2014 03:00am EDT 

Takeda Pharmaceutical Co Ltd:Pfizer Japan Inc.,Takeda Pharmaceutical Company Limited and ASKA Pharmaceutical Co., Ltd announced that they have reached an agreement to conclude their contracts regarding the product SELTOUCH® (“SELTOUCH”, generic name: felbinac), effective Sep. 30.Says distribution and marketing activities for both poultice formulation and tape formulation of Pfizer's transdermal absorption-type analgesic and anti-inflammatory agent SELTOUCH (SELTOUCH PAP 70, SELTOUCH PAP 140, and SELTOUCH TAPE 70) by Takeda and ASKA will be concluded, effective Oct. 1.Pfizer will conduct the distribution and marketing activities for this product.  Full Article

BUZZ-Orexigen Therapeutics Inc: Diet drug launched

** Drugmaker's shares up 20 pct at $4.88, biggest intra-day percentage jump in more than two years

Search Stocks